Awaiting development: Guidance and quality standards

Showing 151 to 160 of 361

Guidance and quality standards awaiting development
Title	Type
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID12207]	Technology appraisal guidance
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies [ID6491]	Technology appraisal guidance
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376]	Technology appraisal guidance
In-situ Normothermic Regional Perfusion system for DCD donors - liver	Interventional procedures guidance
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]	Technology appraisal guidance
Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]	Technology appraisal guidance
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders [ID6430]	Technology appraisal guidance
Inebilizumab for treating generalised myasthenia gravis [TSID12110]	Technology appraisal guidance
Inebilizumab for treating immunoglobulin G4-related disease [TSID12107]	Technology appraisal guidance
Infant, children and young people's experience of health care	Quality standard